Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Corvus Pharmaceuticals (NASDAQ: CRVS).The analyst commented, "Corvus' 4Q25 earning call ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE